Acquisition Chelsea Therapeutics International, Ltd by H. Lundbeck A/S May Not Be in Shareholders' Best Interests

Acquisition Chelsea Therapeutics International, Ltd by H. Lundbeck A/S May Not
                      Be in Shareholders' Best Interests

PR Newswire

SAN DIEGO and CHARLOTTE, N.C., May 12, 2014

SAN DIEGO andCHARLOTTE, N.C., May 12, 2014 /PRNewswire/ --Shareholder rights
attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of
Chelsea Therapeutics International, Ltd (NASDAQ: CHTP) by the private equity
firm H. Lundbeck A/S. On May 8, 2014, the two companies announced the signing
of a definitive merger agreement pursuant to which Lundbeck will commence a
tender offer for all outstanding shares of Chelsea Therapeutics. Under the
agreement, Chelsea Therapeutics shareholders will receive $6.44 in cash for
each share of common stock as well as contingent value rights (CVRs) worth up
to $1.50, for a total possible consideration of $7.94.

Robbins Arroyo LLP.

Is the Proposed Acquisition Best for Chelsea Therapeutics and Its
Shareholders?

Robbins Arroyo LLP's investigation focuses on whether the board of directors
Chelsea Therapeutics is undertaking a fair process to obtain maximum value and
adequately compensate Chelsea Therapeutics shareholders.

As an initial matter, the possible $7.94 merger consideration is significantly
below the target price set by at least three different analysts, including a
target price of $12.00 set by an analyst at JMP securities and a price of
$10.00 set by an analyst at Needham and Co. In addition, on February 18,
2014, the company announced that the U.S. Food and Drug Administration granted
accelerated approval of NORTHERATM (drioxdiopa) for the treatment of
symptomatic neurogenic orthostatic hypotension. According to the company,
NORTHERA is the only therapy approved by the FDA to demonstrate symptomatic
benefit in patients with neurogenic orthostatic hypotension and represents a
"significant marketing opportunity" for the company.

Given these facts, Robbins Arroyo LLP is examining the Chelsea Therapeutics
board of directors' decision to sell the company to Lundbeck. Chelsea
Therapeutics shareholders have the option to file a class action lawsuit to
ensure the board of directors obtains the best possible price for shareholders
and the disclosure of material information. Chelsea Therapeutics interested
in information about their rights and potential remedies can contact attorney
Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the
shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation
and shareholder rights law. The law firm represents individual and
institutional investors in shareholder derivative and securities class action
lawsuits, and has helped its clients realize more than $1 billion of value for
themselves and the companies in which they have invested. 

Attorney Advertising.Past results do not guarantee a similar outcome.

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
ddonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36754LOGO

SOURCE Robbins Arroyo LLP

Website: http://robbinsumeda.com
 
Press spacebar to pause and continue. Press esc to stop.